Brief: Zai Lab Announces Dosing Of First Participant In Global Phase 1/1b Study Of ZL-1503, An IL-13/IL-31R Bispecific Antibody For Treatment Of Atopic Dermatitis
Dec 8 (Reuters) - Zai Lab Ltd 9688.HK: ZAI LAB ANNOUNCES DOSING OF FIRST PARTICIPANT IN GLOBAL PHASE 1/1B STUDY OF ZL-1503, AN IL-13/IL-31R BISPECIFIC ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS Source text: ID:nBw4HYDdDa Further company coverage: 9688.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows